Outlook Therapeutics, Inc. Employee Directory
Biotechnology ResearchNew Jersey, United States51-200 Employees
Outlook Therapeutics, Inc. is a mid-sized biotechnology company based in Cranbury, New Jersey, focused on developing and commercializing ophthalmic therapies for retinal diseases. Its lead candidate, ONS-5010/LYTENAVA (bevacizumab gamma), is an ophthalmic formulation of bevacizumab intended for conditions such as wet age-related macular degeneration. LYTENAVA has received marketing authorization in the European Union and the United Kingdom for wet AMD, and the company plans a commercial launch in the EU and UK in the second quarter of 2025. In the United States, ONS-5010/LYTENAVA remains investigational, with a BLA resubmission to the FDA, and if approved would be the first ophthalmic bevacizumab formulation approved for retinal indications. The company operates in the biotechnology research sector with a focus on expanding access to bevacizumab-based retinal therapy through European distribution and potential U.S. approval. A recent development in its European expansion was an exclusive distribution agreement with Mediconsult AG for LYTENAVA in Switzerland, announced in 2026.
1-888-653-2347 
support@leadiq.com 
